Skip to main content

Table 6 Background of patients stratified by dialysis treatment (peritoneal dialysis or hemodialysis) after matching

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

  Hemodialysis Peritoneal dialysis p valuea
n % n %
Age
 < 60 36 48.0 12 48.0 1.000
 60 s 21 28.0 7 28.0  
 ≥ 70 18 24.0 6 24.0  
Gender
 Male 55 73.3 20 80.0 0.601
 Female 20 26.7 5 20.0  
Primary disease
 Chronic glomerulonephritis 15 21.1 8 36.4 0.507
 Diabetes mellitus 36 50.7 8 36.4  
 Nephrosclerosis 6 8.5 2 9.1  
 Others 14 19.7 4 18.2  
Duration of dialysis
 < 1 year 10 13.7 6 24.0 0.032
 1 to < 5 years 24 32.9 14 56.0  
 5 to < 10 years 22 30.1 5 20.0  
 10 to < 15 years 9 12.3 0 0.0  
 ≥ 15 years 8 11.0 0 0.0  
Complication
 Hypertension
  No 41 54.7 12 50.0 0.815
  Yes 34 45.3 12 50.0  
 Diabetes mellitus
  No 36 48.0 16 66.7 0.159
  Yes 39 52.0 8 33.3  
 Cardiovascular disease
  No 51 69.9 21 87.5 0.110
  Yes 22 30.1 3 12.5  
 Chronic respiratory disease
  No 67 91.8 24 100.0 0.331
  Yes 6 8.2 0 0.0  
 Peripheral arterial disease
  No 64 87.7 23 95.8 0.443
  Yes 9 12.3 1 4.2  
 Malignancy
  No 65 90.3 23 95.8 0.675
  Yes 7 9.7 1 4.2  
 Number of complications
  0 12 16.0 6 25.0 0.164
  1 25 33.3 11 45.8  
  ≥ 2 38 50.7 7 29.2  
Oxygenation
 No 12 16.0 4 16.0 1.000
 Yes 54 72.0 18 72.0  
 Ventilator or ECMO 9 12.0 3 12.0  
Remdesivir
 No 63 87.5 23 95.8 0.443
 Yes 9 12.5 1 4.2  
Dexamethasone
 No 27 37.5 11 45.8 0.481
 Yes 45 62.5 13 54.2  
  1. aFisher’s exact test